{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:24:39Z","timestamp":1649150679430},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","interventional.theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.iccl.2016.08.012","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T02:01:50Z","timestamp":1479866510000},"page":"39-47","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cangrelor"],"prefix":"10.1016","volume":"6","author":[{"given":"Matthew J.","family":"Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iccl.2016.08.012_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.012_bib3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/eurheartj\/ehu160","article-title":"Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial","volume":"35","author":"Lindholm","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.012_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjcard.2006.03.054","article-title":"Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers","volume":"98","author":"Price","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.012_bib8","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.012_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.012_bib12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib13","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jacc.2012.02.042","article-title":"Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2008.02.109","article-title":"Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers","volume":"102","author":"Price","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.012_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.012_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.iccl.2016.08.012_bib18","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12 receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.iccl.2016.08.012_bib20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jcin.2016.04.016","article-title":"The pharmacodynamics of switching between P2Y12 receptor antagonists","volume":"9","author":"Price","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2016.08.012_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.iccl.2016.08.012_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.iccl.2016.08.012_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1538-7836.2008.03020.x","article-title":"The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function","volume":"6","author":"Dovlatova","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.012_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joic.12229","article-title":"Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation","volume":"28","author":"Schneider","year":"2015","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","article-title":"Pharmacodynamic effects during the transition between cangrelor and prasugrel","volume":"26","author":"Schneider","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.iccl.2016.08.012_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.iccl.2016.08.012_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MCA.0000000000000311","article-title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists","volume":"27","author":"Schneider","year":"2016","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.iccl.2016.08.012_bib28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.012_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCULATIONAHA.115.020829","article-title":"Consistent reduction in peri-procedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor versus standard therapy to achieve optimal management of platelet inhibition)","volume":"134","author":"Cavender","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.012_bib30","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2016.08.012_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","volume":"63","author":"Genereux","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2016.08.012_bib33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/eurheartj\/ehv498","article-title":"The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX","volume":"37","author":"Gutierrez","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2016.08.012_bib34","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib35","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.012_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2016.08.012_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/heartjnl-2012-303103","article-title":"A\u00a0novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial","volume":"99","author":"Leonardi","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.iccl.2016.08.012_bib38","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816301067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816301067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:22:18Z","timestamp":1536225738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745816301067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2211745816301067"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.012","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cangrelor","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}